ATOS
Atossa Therapeutics, Inc.
Set alert
2.17 USD -0.06 -2.69%
2.15 Day range 2.43
1.75 52-week range 13.50
- YTD
- -75.48%
- 1 year
- -83.56%
- Open
- 2.25
- Prev close
- 2.23
- Mkt cap
- 21.66M
- Vol
- 32.90K
- Avg vol
- 71.57K
- EPS
- -4.45
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.15
- High
- 2.43
- Forward P/E
- -3.81
- Beta
- 1.23
- Short ratio
- 14.73
- Inst. own
- 28.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.31
- 200-d avg
- 1.39
- 1y target
- 6.00
Key statistics
- Market cap
- 129.58M
- Enterprise value
- 46.47M
- Trailing P/E
- 0.00
- Forward P/E
- -3.81
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.76
- EPS (TTM)
- -0.21
- Beta
- 1.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -12.76M
- Total cash
- 74.77M
- Total debt
- 0
- Return on equity
- -31.30%
- Shares outstanding
- 125.80M
- Short % of float
- 9.23%
- 50-day average
- 1.31
- 200-day average
- 1.39
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 6.00 +176.5% upside
Now 2.17
- Target (low)
- 4.00
- Target (mean)
- 6.00
- Target (high)
- 7.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.06.
Financials — quick view
ATOS Revenue — quarterly 0
ATOS Net income — quarterly -8.49M
ATOS EPS — quarterly -0.95
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.06 | -0.05 | +0.01 | +16.67% |
| Aug 12, 2024 | Jun 1, 2024 | -0.05 | -0.05 | 0.00 | 0.00% |
| May 13, 2024 | Mar 1, 2024 | -0.07 | -0.05 | +0.02 | +28.57% |
| Apr 1, 2024 | Dec 1, 2023 | -0.05 | -0.06 | -0.01 | -20.00% |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.05 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.06 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 9, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 13, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- atossatherapeutics.com
News
- Atossa Therapeutics Confirms Shares To Begin Trading With One Stapled Contingent Value Right As Of Close Of Business On October 19
- Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
- Atossa Therapeutics Inks Stapled Contingent Value Rights Agreement With VStock Transfer; Atossa Declares Dividend Of One Stapled CVR For Each Share Of Atossa Common Stock
- Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
- Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25
- Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
- Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
- Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate
- Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
- Atossa Therapeutics Announces npj Breast Cancer Publication Highlighting Novel Endoxifen-Based Compounds In ESR1-Mutant Breast Cancer Models
Your note
Sign in to keep a note on ATOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FINN JONATHAN F. | Director | Purchase | Apr 9, 2024 | 25,000 |
| WEAVER GREGORY L | Officer and Director | Sale | Nov 14, 2023 | 55 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.68% | 9,667,615 | 9.96M | Sep 29, 2024 |
| Vanguard Group Inc | 5.25% | 6,598,296 | 6.80M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.24% | 2,814,446 | 2.90M | Sep 29, 2024 |
| State Street Corporation | 1.38% | 1,732,221 | 1.78M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.04% | 1,310,070 | 1.35M | Sep 29, 2024 |
| Northern Trust Corporation | 0.76% | 954,199 | 982.82K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.13% | 3,939,441 | 4.06M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.60% | 3,268,268 | 3.37M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.33% | 1,667,748 | 1.72M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.04% | 1,304,195 | 1.34M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.85% | 1,065,227 | 1.10M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 676,434 | 696.73K | Oct 30, 2024 |